Pharmacy News💊
前往频道在 Telegram
This channel is exclusively for pharmacy professionals. Join us if you want access to supportive reading materials and up-to-date information on pharmacy. Be proud to be a pharmacist.For any suggestion contact us via👉 @anikansaati or @Siinandarbe
显示更多3 201
订阅者
+224 小时
+127 天
+4530 天
正在加载数据
吸引订阅者
十月 '2610月 '26
十月 '26
+1 543
在0个频道中
九月 '260
在0个频道中
Get PRO
八月 '260
在0个频道中
Get PRO
七月 '260
在0个频道中
Get PRO
六月 '260
在0个频道中
Get PRO
五月 '260
在0个频道中
Get PRO
四月 '260
在0个频道中
Get PRO
三月 '260
在0个频道中
Get PRO
二月 '260
在0个频道中
Get PRO
一月 '260
在0个频道中
Get PRO
十二月 '250
在0个频道中
Get PRO
十一月 '250
在0个频道中
Get PRO
十月 '250
在0个频道中
Get PRO
九月 '250
在0个频道中
Get PRO
八月 '250
在1个频道中
Get PRO
七月 '250
在0个频道中
Get PRO
六月 '250
在1个频道中
Get PRO
五月 '250
在0个频道中
Get PRO
四月 '250
在0个频道中
Get PRO
三月 '250
在2个频道中
Get PRO
二月 '250
在2个频道中
Get PRO
一月 '250
在1个频道中
Get PRO
十二月 '24
+220
在0个频道中
Get PRO
十一月 '24
+301
在0个频道中
Get PRO
十月 '24
+210
在0个频道中
Get PRO
九月 '24
+103
在0个频道中
Get PRO
八月 '24
+160
在0个频道中
Get PRO
七月 '24
+70
在0个频道中
Get PRO
六月 '24
+50
在0个频道中
Get PRO
五月 '24
+107
在0个频道中
Get PRO
四月 '24
+121
在0个频道中
Get PRO
三月 '24
+116
在0个频道中
Get PRO
二月 '24
+43
在0个频道中
Get PRO
一月 '24
+74
在0个频道中
Get PRO
十二月 '23
+209
在0个频道中
| 日期 | 订阅者增长 | 提及 | 频道 | |
| 31 十月 | +3 | |||
| 30 十月 | +3 | |||
| 29 十月 | +2 | |||
| 28 十月 | +4 | |||
| 27 十月 | +5 | |||
| 26 十月 | +3 | |||
| 25 十月 | +3 | |||
| 24 十月 | +5 | |||
| 23 十月 | +2 | |||
| 22 十月 | +4 | |||
| 21 十月 | +8 | |||
| 20 十月 | +3 | |||
| 19 十月 | +4 | |||
| 18 十月 | +3 | |||
| 17 十月 | +3 | |||
| 16 十月 | +6 | |||
| 15 十月 | 0 | |||
| 14 十月 | +2 | |||
| 13 十月 | +3 | |||
| 12 十月 | +5 | |||
| 11 十月 | +6 | |||
| 10 十月 | +5 |
频道帖子
* Rapid tolerance → tachyphylaxis.
* CYP450 induction → increased metabolism of substrate drugs.
* CYP450 inhibition → decreased metabolism of substrate drugs.
* Prodrugs may have reduced activity with enzyme inhibition.
* Codeine → CYP2D6 → morphine.
* Clopidogrel → CYP2C19 activation.
* Rifampin → CYP450 inducer.
* Grapefruit juice → intestinal CYP3A4 inhibition.
Test yourself: 5 high-yield MCQs
General Pharmacology Quiz
Q1. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady state?
A. 8 hours
B. 16 hours
C. 32–40 hours
D. 64 hours
Q2. A competitive antagonist is added to a full agonist. What happens?
A. Decreased Emax
B. Increased EC50 without changing Emax
C. Decreased EC50
D. Increased Emax
Q3. Which drug follows classic zero-order kinetics?
A. Penicillin
B. Amoxicillin
C. Phenytoin
D. Metoprolol
Q4. A patient with hypoalbuminemia receives warfarin. What happens to its free fraction?
A. Decreases
B. Increases
C. Remains unchanged
D. Drug absorption decreases
Q5. A patient taking rifampin experiences reduced effectiveness of oral contraceptives. What is the mechanism?
A. CYP450 inhibition
B. CYP450 induction
C. Competitive receptor antagonism
D. Reduced renal clearance
Answers to the 5 General Pharmacology MCQs:
* C. 32–40 hours — Steady state occurs after 4–5 half-lives.
* B. Increased EC50 without changing Emax — Competitive antagonist.
* C. Phenytoin — Zero-order kinetics.
* B. Increases — Hypoalbuminemia increases the free fraction of warfarin.
* B. CYP450 induction — Rifampin increases metabolism of oral contraceptives.
#USMLE #USMLEStep1 #usmleprep #pharmacology
| 2 | * Hepatically metabolized drugs may accumulate.
* Reduced albumin can increase the free fraction of highly protein-bound drugs.
* Reduced hepatic metabolism can increase toxicity.
* Examples requiring caution include benzodiazepines, opioids, and warfarin.
Older adults
* Reduced renal function can increase drug accumulation.
* Reduced hepatic metabolism can prolong drug effects.
* Increased sensitivity to sedatives and anticholinergics is common.
* Polypharmacy increases the risk of drug interactions.
* Start with lower doses when clinically appropriate and titrate carefully.
20. Drug Transporters
* Transporters regulate drug movement across cellular membranes.
* P-glycoprotein (P-gp) is an efflux transporter.
* It pumps drugs out of cells.
* It is present in the intestine, liver, kidney, and blood-brain barrier.
* P-gp limits absorption of some drugs and restricts their entry into the brain.
Important examples:
* Digoxin is a P-gp substrate.
* Verapamil inhibits P-gp and can increase digoxin concentrations.
* Rifampin induces P-gp and can reduce digoxin exposure.
21. Important Drug Antidotes – General Pharmacology
These are frequently tested in pharmacology and toxicology.
* Acetaminophen overdose → N-acetylcysteine.
* Opioid overdose → Naloxone.
* Benzodiazepine overdose → Flumazenil (selected cases).
* Warfarin → Vitamin K; 4-factor PCC for major bleeding.
* Unfractionated heparin → Protamine sulfate.
* Dabigatran → Idarucizumab.
* Factor Xa inhibitors → Andexanet alfa in selected cases; PCC may be used depending on the situation.
* Methanol poisoning → Fomepizole.
* Ethylene glycol poisoning → Fomepizole.
* Methotrexate toxicity → Leucovorin.
* Digoxin toxicity → Digoxin-specific antibody fragments.
* Organophosphate poisoning → Atropine + pralidoxime.
* Iron overdose → Deferoxamine.
* Lead poisoning → Chelation therapy, such as succimer in appropriate cases.
* Cyanide poisoning → Hydroxocobalamin.
* Methemoglobinemia → Methylene blue.
* Malignant hyperthermia → Dantrolene.
* Isoniazid-induced seizures → Pyridoxine (vitamin B6).
* Beta-blocker overdose → Glucagon (among other treatments).
* Calcium-channel blocker overdose → IV calcium and high-dose insulin therapy.
22. Important USMLE Pharmacology Formulas
Memorize these formulas for calculation-based questions.
Volume of distribution
Vd=Amount of drug in body/Plasma concentration
Clearance
CL=Rate of eliminatio/Plasma concentration
Half-life
t1/2=0.693 * Vd/CL
Loading dose
LD=Vd * Target concentration/F
Maintenance dose rate
MD= CL * Target concentration/F
Therapeutic index
TI=TD50/ED50
Bioavailability
F= AUC(oral)/AUC(IV) * 100
(For equal doses.)
23. Last-Minute USMLE High-Yield MCQ Pearls
* IV administration → 100% bioavailability.
* First-pass metabolism → decreased oral bioavailability.
* High Vd → extensive tissue distribution.
* High plasma protein binding → generally low Vd.
* Hypoalbuminemia → increased free fraction of albumin-bound drugs.
* Increased clearance → decreased half-life.
* Increased Vd → increased half-life if clearance remains unchanged.
* Five half-lives → approximately 97% eliminated.
* Steady state → approximately 4–5 half-lives.
* Loading dose → depends primarily on Vd.
* Maintenance dose → depends primarily on clearance.
* First-order kinetics → constant fraction eliminated.
* Zero-order kinetics → constant amount eliminated.
* Phenytoin, ethanol, high-dose aspirin → classic zero-order examples.
* Competitive antagonist → increased EC50, unchanged Emax.
* Noncompetitive antagonist → decreased Emax.
* Partial agonist → lower maximal efficacy than full agonist.
* Lower EC50 → greater potency.
* Higher Emax → greater efficacy.
* Narrow therapeutic index → close monitoring.
* Chronic receptor blockade → upregulation.
* Chronic receptor stimulation → downregulation. | 168 |
| 3 | * Pharmacodynamic interactions affect the drug’s physiological effect.
* Additive effects occur when combined effects equal the sum of individual effects.
* Synergistic effects occur when the combined effect exceeds the expected additive effect.
* Antagonistic effects occur when one drug reduces the effect of another.
Important examples:
* Benzodiazepines + opioids → synergistic respiratory depression.
* Alcohol + benzodiazepines → increased CNS depression.
* NSAIDs + warfarin → increased bleeding risk.
* ACE inhibitors + spironolactone → hyperkalemia.
* Nitrates + sildenafil → severe hypotension.
* Metoprolol + verapamil → bradycardia and AV block.
* Rifampin + oral contraceptives → reduced contraceptive effectiveness.
17. Routes of Drug Administration
Intravenous (IV)
* Directly enters systemic circulation.
* Bioavailability = 100%.
* Fastest and most predictable systemic delivery.
* No absorption phase.
* Cannot be easily reversed once administered.
Intramuscular (IM)
* Drug is injected into muscle.
* Absorption depends on blood flow.
* Can be used for depot preparations.
* Some drugs have prolonged release from IM preparations.
Subcutaneous (SC)
* Drug is injected into subcutaneous tissue.
* Absorption is generally slower than IM.
* Examples: Insulin and heparin.
Oral (PO)
* Convenient and noninvasive.
* Subject to first-pass metabolism.
* Absorption can be affected by food and GI conditions.
* Not suitable for unconscious patients or patients unable to swallow safely.
Sublingual
* Drug is absorbed through oral mucosa.
* Bypasses hepatic first-pass metabolism.
* Rapid absorption.
* Example: Nitroglycerin.
Transdermal
* Drug crosses the skin into systemic circulation.
* Avoids first-pass metabolism.
* Provides sustained drug delivery.
* Examples: Nicotine patch, fentanyl patch, scopolamine patch.
Rectal
* Some rectal venous drainage bypasses the portal circulation.
* First-pass metabolism is partially avoided.
* Useful when oral administration is not possible.
18. Pharmacogenetics
* Pharmacogenetics studies how genetic variation affects drug response.
* Genetic differences can affect drug metabolism, transport, and receptor sensitivity.
* CYP450 polymorphisms can produce poor, intermediate, normal, or ultrarapid metabolizers.
High-yield examples:
CYP2D6
* Codeine requires CYP2D6 conversion to morphine.
* Poor metabolizers may have inadequate analgesia.
* Ultrarapid metabolizers may develop opioid toxicity.
CYP2C19
* Activates clopidogrel.
* Poor metabolizers have reduced antiplatelet response.
* May increase the risk of cardiovascular events.
TPMT / NUDT15
* Metabolize thiopurines such as azathioprine and 6-mercaptopurine.
* Reduced activity increases the risk of severe myelosuppression.
HLA-B*5701
* Associated with abacavir hypersensitivity.
* Test before starting abacavir.
HLA-B*1502
* Associated with Stevens-Johnson syndrome/toxic epidermal necrolysis from carbamazepine, especially in certain Asian ancestry populations.
* Screening is recommended in at-risk populations before starting carbamazepine.
HLA-B*5801
* Associated with allopurinol-induced severe cutaneous adverse reactions.
* Consider screening in high-risk populations.
G6PD deficiency
* Oxidative medications can cause hemolytic anemia.
* Examples: Primaquine, dapsone, rasburicase, and nitrofurantoin.
19. Special Populations and Drug Dosing
Pregnancy
* Drugs can cross the placenta depending on molecular properties.
* Lipid-soluble, low-molecular-weight drugs generally cross more easily.
* Warfarin is teratogenic.
* ACE inhibitors and ARBs are contraindicated during pregnancy.
* Isotretinoin is highly teratogenic.
* Valproate increases neural tube defect risk.
* Tetracyclines can affect fetal teeth and bones.
Renal impairment
* Renally eliminated drugs may accumulate.
* Dose adjustment or longer dosing intervals may be needed.
* Examples include aminoglycosides, vancomycin, and digoxin.
* Monitor renal function and drug levels when indicated.
Hepatic impairment | 96 |
| 4 | * Leftward dose-response curve = increased potency.
* Higher maximum response = increased efficacy.
* Competitive antagonist = rightward shift without decreasing Emax.
* Noncompetitive antagonist = decreased Emax.
12. Therapeutic Index (TI)
* Therapeutic index measures the relative safety of a drug.
* It compares the toxic dose with the effective dose.
* A higher therapeutic index generally means a safer drug.
* A lower therapeutic index means the therapeutic and toxic concentrations are closer.
* Drugs with narrow therapeutic indices require close monitoring.
Formula:
TI=TD50/ED50
* TD50 = Dose producing toxicity in 50% of the population.
* ED50 = Dose producing the desired effect in 50% of the population.
Drugs with narrow therapeutic indices:
* Warfarin
* Digoxin
* Lithium
* Phenytoin
* Theophylline
* Aminoglycosides
* Cyclosporine
* Tacrolimus
USMLE clue: A patient develops toxicity despite a small increase in drug dose. Think narrow therapeutic index.
13. Receptor Regulation
Upregulation
* Upregulation means an increase in receptor number or sensitivity.
* It can occur after prolonged receptor blockade.
* Cells increase receptor expression to compensate for reduced stimulation.
Example:
* Chronic beta-blocker use increases beta-receptor expression.
* Abrupt discontinuation can cause rebound tachycardia and hypertension.
Downregulation
* Downregulation means a decrease in receptor number or sensitivity.
* It occurs after prolonged stimulation of receptors.
* It decreases cellular responsiveness to an agonist.
Example:
- Chronic exposure to beta-agonists can decrease beta-receptor responsiveness.
Remember:
* Chronic antagonist → receptor upregulation.
* Chronic agonist → receptor downregulation.
14. Tolerance and Tachyphylaxis
Tolerance
* Tolerance means decreased response to a drug after repeated administration.
* A higher dose may be required to achieve the same effect.
* It can occur because of receptor downregulation or increased drug metabolism.
* It generally develops over days to weeks, although the time course varies.
Examples:
* Opioids
* Benzodiazepines
* Alcohol
* Nitrates
Tachyphylaxis
* Tachyphylaxis is rapidly developing tolerance.
* It occurs after repeated doses over a short period.
* It may result from depletion of stored neurotransmitters or receptor desensitization.
Examples:
* Ephedrine: depletion of norepinephrine stores.
* Indirect sympathomimetics can develop tachyphylaxis.
USMLE clue: Repeated doses produce progressively smaller effects within a short time → tachyphylaxis.
15. Adverse Drug Reactions
Type A reactions
* Augmented pharmacologic effects.
* Dose-dependent.
* Predictable.
* Usually more common.
* Often preventable by adjusting the dose.
Examples:
* Insulin → hypoglycemia.
* Warfarin → bleeding.
* Opioids → respiratory depression.
* Antihypertensives → hypotension.
Type B reactions
* Bizarre reactions.
* Usually unpredictable.
* Not directly related to the usual pharmacologic effect.
* Often associated with allergy or idiosyncrasy.
* Can occur even at normal therapeutic doses.
Examples:
* Penicillin → anaphylaxis.
* Sulfonamides → severe hypersensitivity reactions.
* Genetic G6PD deficiency → hemolysis after certain oxidative drugs.
Other important adverse reactions
* Type C: Chronic use-related reactions.
* Type D: Delayed reactions.
* Type E: End-of-use or withdrawal reactions.
* Type F: Failure of therapy.
High-yield examples:
* Long-term glucocorticoids → osteoporosis (Type C).
* Teratogenicity → delayed effect (Type D).
* Abrupt clonidine discontinuation → rebound hypertension (Type E).
* Antibiotic treatment failure due to resistance → Type F.
16. Drug Interactions
* Drug interactions occur when one drug alters the effect of another drug.
* Pharmacokinetic interactions affect absorption, distribution, metabolism, or excretion. | 82 |
| 5 | * Fluoxetine and paroxetine inhibit CYP2D6.
* Amiodarone inhibits several CYP enzymes.
* Ritonavir inhibits CYP3A4.
Clinical examples:
* Erythromycin + simvastatin → increased statin concentration → rhabdomyolysis risk.
* Fluoxetine + metoprolol → increased metoprolol exposure → bradycardia risk.
* Grapefruit juice inhibits intestinal CYP3A4 → increased levels of certain medications.
Important exception: CYP induction or inhibition does not always produce the same clinical effect with prodrugs.
* Inhibition of codeine activation by CYP2D6 can decrease morphine formation and analgesia.
* Inhibition of clopidogrel activation by CYP2C19 can decrease its antiplatelet effect.
8. First-Order vs Zero-Order Kinetics
First-order kinetics
* Most drugs follow first-order kinetics.
* A constant fraction of the drug is eliminated per unit time.
* The elimination rate is proportional to drug concentration.
* Half-life remains constant.
* Increasing drug concentration increases the amount eliminated per unit time.
Examples:
* Penicillin
* Most beta-blockers
* Most antibiotics
Zero-order kinetics
* A constant amount of drug is eliminated per unit time.
* Elimination enzymes become saturated.
* Half-life is not constant.
* A small increase in dose can cause a disproportionately large increase in plasma concentration.
* Drug accumulation and toxicity are important concerns.
Three classic USMLE examples:
* Phenytoin
* Ethanol
* Aspirin at high doses
MCQ clue: A drug’s elimination becomes saturated, and its plasma concentration rises disproportionately after a small dose increase.
Answer: Zero-order kinetics.
9. Pharmacodynamics
Pharmacodynamics = What the drug does to the body.
* Pharmacodynamics describes the relationship between drug concentration and drug effect.
* Drugs act by interacting with receptors, enzymes, ion channels, or transporters.
* Agonists activate receptors.
* Antagonists block receptor activation.
* Partial agonists produce a submaximal response even when all receptors are occupied.
* Inverse agonists decrease constitutive receptor activity.
10. Agonists and Antagonists
Full agonist
* Binds to a receptor.
* Has affinity for the receptor.
* Has intrinsic activity.
* Produces maximal receptor activation when sufficient receptors are available.
Example: Morphine is a full agonist at the mu-opioid receptor.
Partial agonist
* Binds to the same receptor as a full agonist.
* Produces a lower maximal response.
* Has lower intrinsic efficacy than a full agonist.
* Can act as a functional antagonist in the presence of a full agonist.
Examples:
* Buprenorphine = partial mu-opioid agonist.
* Aripiprazole = partial dopamine D2 agonist.
* Pindolol = partial beta-adrenergic agonist.
Competitive antagonist
* Competes with an agonist for the same receptor binding site.
* Its effect can be overcome by increasing agonist concentration.
* It causes a rightward shift in the dose-response curve.
* It increases EC50.
* It does not change Emax.
Example: Naloxone competitively antagonizes opioid receptors.
Noncompetitive antagonist
* Binds irreversibly to the receptor or binds to an allosteric site.
* Cannot be overcome by simply increasing agonist concentration.
* Decreases the maximal response (Emax).
* Reduces the number of functional receptors or receptor signaling.
Example: Phenoxybenzamine irreversibly blocks alpha receptors.
11. Potency vs Efficacy
Potency
* Potency refers to the amount of drug required to produce a particular effect.
* More potent drugs require lower doses to produce the same effect.
* EC50 is the concentration producing 50% of maximal effect.
* Lower EC50 means higher potency.
Efficacy
* Efficacy refers to the maximum effect a drug can produce.
* Emax measures maximal efficacy.
* A full agonist has greater efficacy than a partial agonist at the same receptor system.
* Increasing the dose of a partial agonist cannot produce the same maximum response as a full agonist in the same system.
USMLE clue: | 86 |
| 6 | Answer: Approximately 24–30 hours.
4. Steady-State Concentration
* Steady state occurs when the rate of drug administration equals the rate of drug elimination.
* It usually takes 4–5 half-lives to achieve steady state.
* Increasing the dose increases steady-state concentration.
* Increasing the dosing frequency increases steady-state concentration if the dose per administration remains unchanged.
* Decreasing clearance increases steady-state concentration.
* Steady state can be achieved faster with a loading dose.
* A loading dose is used when rapid therapeutic drug concentrations are needed.
* A maintenance dose maintains the desired steady-state concentration.
Important formulas:
Loading dose:
LD=Target concentration * Vd/F
Maintenance dose rate:
MD rate=Target concentration * CL/F
Clinical examples:
* Digoxin: Loading dose may be used when rapid therapeutic effect is required.
* Vancomycin: Loading doses can be used in selected severe infections.
* Phenytoin: Loading dose can rapidly achieve therapeutic concentrations in seizures.
5. Drug Metabolism
* Drug metabolism is the chemical modification of drugs, mainly in the liver.
* The liver is the major site of drug metabolism.
* Metabolism usually makes drugs more water-soluble for renal excretion.
* Some drugs are converted into inactive metabolites.
* Some drugs are converted into active metabolites.
* Some drugs are prodrugs that require metabolism for activation.
Phase I reactions
* Phase I reactions include oxidation, reduction, and hydrolysis.
* Cytochrome P450 enzymes are important in Phase I metabolism.
* Phase I reactions introduce or expose functional groups.
* CYP450 enzymes are mainly located in the smooth endoplasmic reticulum of hepatocytes.
* Phase I metabolism may activate, inactivate, or occasionally produce toxic metabolites.
Examples:
* Diazepam → active metabolites.
* Codeine → morphine through CYP2D6.
* Clopidogrel → active metabolite through CYP2C19.
Phase II reactions
* Phase II reactions involve conjugation.
* Glucuronidation is a major Phase II reaction.
* Other reactions include sulfation, acetylation, methylation, and glutathione conjugation.
* Conjugation generally increases water solubility.
* Phase II reactions usually produce inactive metabolites, although exceptions exist.
High-yield examples:
* Acetaminophen is metabolized mainly by glucuronidation and sulfation.
* A small fraction is metabolized by CYP450 to NAPQI, a toxic metabolite.
* Glutathione detoxifies NAPQI.
* In acetaminophen overdose, glutathione becomes depleted.
* N-acetylcysteine replenishes glutathione and treats acetaminophen toxicity.
6. Cytochrome P450 Enzyme Inducers
* Enzyme induction increases CYP450 enzyme activity.
* It increases metabolism of drugs that are CYP substrates.
* It can decrease plasma concentrations and therapeutic effects of active drugs.
* Enzyme induction can take days to weeks because new enzyme synthesis is required.
* Prodrugs may become more active if induction increases their activation.
Mnemonic: CRAP GPS
* C = Carbamazepine
* R = Rifampin
* A = Alcohol (chronic use)
* P = Phenytoin
* G = Griseofulvin
* P = Phenobarbital
* S = St. John’s wort
Additional important inducer:
- Smoking induces CYP1A2.
Clinical examples:
* Rifampin decreases the effectiveness of oral contraceptives.
* Carbamazepine can decrease warfarin concentrations.
* Phenytoin can decrease the effectiveness of many drugs.
* Smoking increases metabolism of CYP1A2 substrates, such as theophylline.
7. Cytochrome P450 Enzyme Inhibitors
* Enzyme inhibition decreases CYP450 enzyme activity.
* It decreases metabolism of active drugs.
* This can increase plasma drug concentrations.
* Increased drug concentration can cause toxicity.
* Enzyme inhibition can occur relatively quickly.
Mnemonic:
* C = Cimetidine
* C = Ciprofloxacin
* M = Macrolides (especially erythromycin and clarithromycin)
* A = Azole antifungals
* G = Grapefruit juice
* I = Isoniazid
* V = Valproate
* S = Sulfonamides
Additional examples: | 113 |
| 7 | General Pharmacology: If you go through this thoroughly, I promise you won’t miss a single General Pharmacology question 🔥🔥💯
1. Pharmacokinetics
Pharmacokinetics = What the body does to the drug.
Four major processes:
* Absorption
* Distribution
* Metabolism
* Excretion
Absorption
* Absorption is the movement of a drug from its administration site into systemic circulation.
* Most drugs are absorbed by passive diffusion.
* Lipid-soluble drugs cross cell membranes more easily.
* Nonionized drugs cross membranes more easily than ionized drugs.
* Weak acids are more nonionized in acidic environments.
* Weak bases are more nonionized in alkaline environments.
* Most drug absorption occurs in the small intestine because of its large surface area.
* First-pass metabolism occurs when an orally administered drug passes through the intestinal wall and liver before reaching systemic circulation.
* First-pass metabolism decreases oral bioavailability.
* Sublingual, transdermal, and IV administration bypass hepatic first-pass metabolism.
Bioavailability (F)
* Bioavailability is the fraction of an administered drug that reaches systemic circulation unchanged.
* IV administration has 100% bioavailability.
* Oral drugs usually have less than 100% bioavailability.
* First-pass metabolism decreases bioavailability.
* Bioavailability can be affected by absorption and hepatic metabolism.
Distribution
* Distribution is the movement of a drug from blood into tissues.
* Highly lipid-soluble drugs distribute widely into tissues.
* Highly protein-bound drugs remain more in the plasma.
* Albumin mainly binds acidic drugs.
* Alpha-1 acid glycoprotein mainly binds basic drugs.
* Only the free (unbound) drug is pharmacologically active, freely filtered by the glomerulus, and available for metabolism.
* Hypoalbuminemia increases the free fraction of highly albumin-bound drugs.
* This can increase drug toxicity.
Volume of Distribution (Vd)
* Vd = Amount of drug in the body / Plasma drug concentration.
* High Vd means the drug is extensively distributed into tissues.
* Low Vd means the drug remains mainly in the bloodstream.
* Lipid-soluble drugs generally have a high Vd.
* Highly plasma protein-bound drugs generally have a low Vd.
* Edema and ascites can increase Vd of water-soluble drugs.
High-yield clinical example:
Digoxin has a large volume of distribution because it accumulates in tissues, particularly skeletal and cardiac muscle.
2. Drug Clearance
* Clearance is the volume of plasma cleared of a drug per unit time.
* Clearance measures the body’s ability to eliminate a drug.
* Total clearance = Renal clearance + Hepatic clearance + Other clearance.
* Increased clearance decreases plasma drug concentration.
* Decreased clearance increases plasma drug concentration.
* Renal impairment decreases clearance of renally eliminated drugs.
* Liver disease can decrease clearance of drugs metabolized by the liver.
* Creatinine clearance is commonly used to estimate renal function for drug dosing.
* Drugs with narrow therapeutic indices require closer monitoring when renal or hepatic function changes.
High-yield formula:
CL = \frac{\text{Rate of elimination}}{\text{Plasma concentration}}
3. Half-life (t½)
* Half-life is the time required for plasma drug concentration to decrease by 50%.
* After one half-life, 50% of the drug remains.
* After two half-lives, 25% remains.
* After three half-lives, 12.5% remains.
* After four half-lives, 6.25% remains.
* After five half-lives, approximately 3% remains.
* Approximately 4–5 half-lives are required to reach steady state.
* Approximately 4–5 half-lives are also required to eliminate most of a drug after discontinuation.
* Long half-life means the drug remains in the body longer.
* Short half-life means the drug is eliminated more rapidly.
* Decreased renal or hepatic clearance can increase half-life.
* Increased volume of distribution can increase half-life.
Formula:
t1/2=0.693 * Vd/CL
USMLE clue: A drug has a half-life of 6 hours. How long will it take to reach steady state? | 218 |
| 8 | KDIGO-2027-CKD-Guideline-Focused-Update-Public-Review-Draft.pdf | 470 |
| 9 | 2026 WHO Malaria Guideline.pdf | 1 131 |
| 10 | +1 Textbook of Clinical Pharmacology 2025.pdf | 1 685 |
| 11 | Probiotics_Prescribed_With_Helicobacter_pylori_Eradication_Therapy.pdf | 1 641 |
| 12 | +1 Sedation and analgesia in the critically ill.pdf | 1 620 |
| 13 | Rook's_Textbook_of_Dermatology,_4_Volume_Set,_Tenth_Edition_John.pdf | 1 557 |
| 14 | 2020_Poisoning_and_Drug_Overdose_ManagementTrainingfor_HealthCare.pdf | 1 648 |
| 15 |  Happy Oromo people's thanks giving day!
Happy Irreechaa🥰 | 1 729 |
| 16 |  Happy Meskel Holiday to all Christian followers🥰 | 1 402 |
| 17 |  没有文字... | 1 410 |
| 18 |  Happy Ethiopian New Year 🎊🎊🎊 | 1 235 |
| 19 | WHO guidelines for malaria - 10 September 2026 | 1 595 |
| 20 |  🌼 መልካም አዲስ ዓመት! | Happy Enkutatash! 🌼
Baga Bara Haaraa Geessan!
To all members of Pharmacy News:
May this New Year bring fresh energy, academic triumphs, clinical excellence, and boundless success to your journey in healthcare!
━━━━━━━━━━━━━━━━━━━━
℞: Peace, Robust Health, Joy & Prosperity
Sig: Take daily all year long. Refills: Unlimited! 💊✨
━━━━━━━━━━━━━━━━━━━━
Wishing you and your families a blessed and prosperous Ethiopian New Year!
Warm regards,
Pharmacist Kenenisa S.
Founder & Admin, Pharmacy News
(#Enkutatash #PharmacyNews #MelkamAddisAmet 🌼🇪🇹) | 1 724 |
